|Datasheet||Specific References||Reviews||Related Products||Protocols|
|Vector Type||Mammalian Expression Vector|
|Expression Method||Constiutive, Stable / Transient|
|Selection In Mammalian Cells||Hygromycin|
A myc tag can be used in many different assays that require recognition by an antibody. If there is no antibody against the studied protein, adding a myc-tag allows one to follow the protein with an antibody against the Myc epitope. Examples are cellular localization studies by immunofluorescence or detection by Western blotting.
The peptide sequence of the myc-tag is: N-EQKLISEEDL-C (1202 Da). It can be fused to the C-terminus and the N-terminus of a protein. It is advisable not to fuse the tag directly behind the signal peptide of a secretory protein, since it can interfere with translocation into the secretory pathway.
|Human FOLH1 ORF mammalian expression plasmid, C-GFPSpark tag||HG15877-ACG|
|Human FOLH1 ORF mammalian expression plasmid, C-OFPSpark / RFP tag||HG15877-ACR|
|Human FOLH1 ORF mammalian expression plasmid, C-Flag tag||HG15877-CF|
|Human FOLH1 ORF mammalian expression plasmid, C-His tag||HG15877-CH|
|Human FOLH1 ORF mammalian expression plasmid, C-Myc tag||HG15877-CM|
|Human FOLH1 ORF mammalian expression plasmid, C-HA tag||HG15877-CY|
|Human FOLH1 Gene cDNA clone plasmid||HG15877-G|
|Human FOLH1 ORF mammalian expression plasmid, N-Flag tag||HG15877-NF|
|Human FOLH1 ORF mammalian expression plasmid, N-His tag||HG15877-NH|
|Human FOLH1 ORF mammalian expression plasmid, N-Myc tag||HG15877-NM|
|Human FOLH1 ORF mammalian expression plasmid, N-HA tag||HG15877-NY|
|Human FOLH1 natural ORF mammalian expression plasmid||HG15877-UT|
|Learn more about expression Vectors|
Glutamate carboxypeptidase 2, also known as Glutamate carboxypeptidase II, Membrane glutamate carboxypeptidase, Prostate-specific membrane antigen, GCPII, PSMA, FOLH1, and NAALAD1, is a single-pass type I I membrane protein which belongs to the peptidase M28 family and M28B subfamily. FOLH1 is highly expressed in prostate epithelium. It is detected in urinary bladder, kidney, testis, ovary, fallopian tube, breast, adrenal gland, liver, esophagus, stomach, small intestine, colon, brain (at protein level), and the capillary endothelium of a variety of tumors. FOLH1 has both folate hydrolase and N-acetylated alpha linked acidic dipeptidase (NAALADase) activity. It has a preference for tri-alpha-glutamate peptides. Genetic variation in FOLH1 may be associated with low folate levels and consequent hyperhomocysteinemia. This condition can result in increased risk of cardiovascular disease, neural tube defects, and cognitive deficits. FOLH1 also shows a promising role in directed imaging and therapy of recurrent or metastatic disease.